HTA Quarterly | Winter 2019

By Xcenda

In this issue, we take a closer look at the utilization of multiple criteria decision analysis (MCDA) in health technology appraisals, newer therapies for Cystic Fibrosis, and the regulatory pathways and complexity of health technology assessment (HTA) evidentiary hurdles for new diabetes drugs, devices, and combination technologies.


MCDA: Too Much Talk, Too Little Progress?

Using a structured explicit approach for decisions involving multiple criteria can improve the quality of decision making. For complex problems like health technology appraisals, a set of techniques known under the collective heading of “multiple criteria decision analysis” (MCDA) can be helpful for this purpose. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force has defined MCDA as a set of techniques, originating from operations research, that “[provide] clarity on which criteria are relevant, the importance attached to each [criteria], and how to use [that] information in a framework [to assess] the available alternatives.”


Assessment of Emerging Therapies for Cystic Fibrosis

Cystic fibrosis (CF) is a complex, genetic disease that affects the respiratory system, digestive system, and other organs due to the production of an abnormally thick mucus that causes obstructions in airways, ducts, and passageways throughout the body. We examine newer therapies that target the cystic fibrosis membrane conductance regulator (CFTR) protein work to treat the underlying cause of disease.


Diabetes and the Growing Investment in Drugs, Devices, and Diagnostics

The rising global demand for diabetes management options, driven by demographic and risk factor changes, has stimulated the development of many novel diabetes medications, drug-device combinations, and drug-device-diagnostic combinations designed to advance patient care and provide salient benefits to patients. We explore the regulatory pathways and complexity of health technology assessment (HTA) evidentiary hurdles for new diabetes drugs, devices, and combination technologies.

Heard on the Street

“This exciting new international collaboration between two established HTA bodies will help pharmaceutical companies develop relevant evidence for CADTH and NICE while streamlining the process of obtaining advice in two distinct markets.”

– Michelle Mujoomdar, Acting Vice President, Evidence Standards, CADTH. Commenting on the NICE / CADTH collaboration for parallel scientific advice.

HTA by the Numbers


The PhRMA Foundation has announced grants totaling $1,000,000 as part of its Value Assessment Initiative. The aim of the initiative is to develop transformative, multi-stakeholder-driven solutions that address challenges in assessing the value of medicines and healthcare services and ultimately improve patient outcomes and reduce inefficiency. The $1,000,000 will be distributed to new centers located at Tufts Medical Center and the University of Colorado.
Tufts’ Center for Enhanced Value Assessment (CEVA) will be directed by Peter J. Neumann, ScD. CEVA’s mission will include: exploring development of additional value elements; engaging patients and stakeholders to identify important novel and non-standard elements; and reporting findings back to stakeholders.
The University of Colorado’s Center for Pharmaceutical Value (PValue), under the direction of Jonathan D. Campbell, PhD, will apply and test novel methods to improve the pharmaceutical coverage and reimbursement decision-making process, with the goal of improving transparency, consistency, and personalization of decisions through multi-criteria decision analysis (MCDA).

Map of Europe

HTA Decision Map

Map of Europe
Find detailed information on product decisions in Australia, Canada, France, Germany, and the United Kingdom with our HTA Decision Map.
Map of Europe